Kalaris Therapeutics, Inc.
News
(2)April 2026
Kalaris Therapeutics, Inc. — S-3 Filing
# 🧾 What This Document Is This is an **S-3 registration statement**, essentially a "permission slip" from the SEC. It allows specific existing shareholders of Kalaris Therapeutics to sell their shares to the public on the open market. Think of it as the company facilitating a secondary sale, not ra
Kalaris Therapeutics, Inc. — S-3 Filing
# 🧾 What This Document Is This is an **S-3 filing** with the SEC, specifically containing an **Indenture** for **subordinated debt securities**. Think of it as the master rulebook the company will follow if it decides to issue corporate bonds (IOUs) to investors in the future. It doesn't issue any
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.